From Nasdaq:

DaVita is a major provider of dialysis services for patients with chronic kidney failure. It shares the kidney care market with Fresenius and is known for its treatments in hospitals, at home, and outpatient centers. The stock has had a compound annual return of 10.8% and has a Zacks Rank #1 rating, making it an attractive investment opportunity.

Earnings estimates for DaVita have been climbing higher, with last quarter’s EPS coming in 48.4% above expectations. FY23 earnings are expected to grow 22.3% to $8.07 per share, while FY24 earnings are forecast to increase by 5% to $8.46 per share, indicating strong performance.

DaVita is known for its large share repurchase programs, having reduced its total share count by 57% over the last ten years. Its current valuation is historically discounted, with a one year forward earnings multiple of 13x and a PEG Ratio of 0.75x, suggesting that it is cheap based on its growth.

With its low relative valuation and expected high earnings growth, DaVita is considered a fantastic investment opportunity. It is also a top-ranked healthcare stock and has an “A” across the Value, Growth, and VGM style scores, making it a top consideration for investors.
Zacks Investment Research is naming its top 10 stocks for 2024, and investors are encouraged to grab the opportunity to learn about these top picks early for potentially outstanding performance.



Read more: Bull of the Day: DaVita (DVA)